ArticlebioRxiv : the preprint server for biology2026
Atlas-Level Single-Cell and Spatial Transcriptomics Data Integration via PRIME.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) have enabled atlas-scale cellular cartography, with consortium efforts now assembling millions of cells across diverse tissues, donors, and technologies to build comprehensive references for cell identify and disease mechanism, yet the scientific value of these atlases hinges on robust computational integration across heterogeneous data sources. Unlike pairwise batch correction, atlas-level integration must jointly reconcile heterogeneous and often hierarchically nested batch effects across many datasets whose cell-type compositions are highly imbalanced, all while preserving subtle biological variation and remaining computationally tractable at the scale of millions of cells. Existing approaches often prioritize either batch mixing or preservation of local biological structure, and most cannot natively accommodate spatial coordinates. Here we introduce PRIME (Projection-based Robust Integration via Manifold Embedding), an ensemble integration framework that combines random-projection-based consensus anchoring, graph-Laplacian correction, and optional spatial-neighborhood regularization. Across multiple random projections of the expression manifold, PRIME uses consensus voting to keep only cell pairs that repeatedly matched, reducing false anchors caused by projection-specific distortions. For ST, PRIME couples this expression-based anchor graph with a coordinate-derived spatial neighborhood graph in a unified graph-Laplacian objective with closed-form solution, enabling simultaneous cross-batch alignment and local spatial coherence. Based on extensive benchmarking spanning diverse datasets, we show that PRIME consistently outperforms state-of-the-art methods in both batch correction and biological conservation across scRNA-seq and ST integration scenarios and downstream tasks including trajectory inference, spatial-domain preservation, and perturbation-response analysis. Particularly, when integrating a human hematopoiesis benchmark spanning eight donors and approximately 33,000 cells, PRIME preserves biologically coherent developmental trajectories in human hematopoiesis. It also maintains cortical laminar architecture across dorsolateral prefrontal cortex sections in a ST dataset and recovers known drug-target relationships in a perturbation atlas of more than 1 million cells while suppressing batch-associated confounders. Together, these results establish PRIME as a versatile and scalable framework for atlas-level integration of scRNA-seq and ST across diverse biological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.